Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT01748123
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 37
- Registration Number
- NCT01712139
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 40
- Registration Number
- NCT01712126
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 90
- Registration Number
- NCT01692717
- Locations
- 🇧🇷
LAL Clínica Pesquisa e Desenvolvimento Ltda, Valinhos, São Paulo, Brazil
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: LCZ696 matching placebo
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 454
- Registration Number
- NCT01692301
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
- Conditions
- HypertensionPlasma Renin Activity
- Interventions
- Drug: lisinopril/hydrochlorothiazide
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 17
- Registration Number
- NCT01658657
- Locations
- 🇺🇸
UNC Chapel Hill, Chapel Hill, North Carolina, United States
Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Spanish Society of Internal Medicine
- Target Recruit Count
- 232
- Registration Number
- NCT01647932
- Locations
- 🇪🇸
Internal Medicine Service, Hospital d'Olot (Girona), Olot, Girona, Spain
Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- EMS
- Target Recruit Count
- 636
- Registration Number
- NCT01620788
- Locations
- 🇧🇷
Allergisa, Campinas, São Paulo, Brazil
Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 24
- Registration Number
- NCT01519635
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries
- Conditions
- HypertensionDiabetes
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Registration Number
- NCT01480791
- Locations
- 🇨🇦
Cardiovascular Prevention Centre, Jewish General Hospital, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.